{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:12:13Z","timestamp":1790514733352,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"crossref","award":["2011\/20135-2"],"award-info":[{"award-number":["2011\/20135-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CEPID","award":["201308135-2"],"award-info":[{"award-number":["201308135-2"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bcmd.2016.03.008","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T23:18:37Z","timestamp":1460243917000},"page":"25-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"59","author":[{"given":"Maria Gabriela","family":"Berzoti-Coelho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Fernanda","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"de Souza Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Tomazini","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maur\u00edcio Cristiano Rocha","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda Pinto","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00ednez-A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Xisto","family":"Souto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Alexandre","family":"Panepucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas Tadeu","family":"Covas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Kashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fab\u00edola Atti\u00e9","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.03.008_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2004.02.011","article-title":"The chronic myeloproliferative disorders: clonality and clinical heterogeneity","volume":"41","author":"Spivak","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00062752-199704010-00002","article-title":"The function of BCR\/ABL and related proto-oncogenes","volume":"4","author":"Gotoh","year":"1997","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/0971-6866.132758","article-title":"A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology","volume":"20","author":"Iqbal","year":"2014","journal-title":"Indian J. Hum. Genet."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0030","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","article-title":"A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects","volume":"11","author":"James","year":"2005","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0035","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0040","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1182\/blood-2009-04-217406","article-title":"Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders","volume":"114","author":"Zhaohui","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/jcp.2010.080895","article-title":"Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases","volume":"64","author":"Tognon","year":"2011","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0050","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1590\/S1679-45082013000400025","article-title":"Apoptosis deregulation in myeloproliferative neoplasms","volume":"11","author":"Tognon","year":"2013","journal-title":"Einstein (Sao Paulo)"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0055","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000369446","article-title":"Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy","volume":"133","author":"Ferreira","year":"2015","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0060","article-title":"New insights into the molecular resistance mechanisms of chronic myeloid leukemia","author":"Huang","year":"2015","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0065","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1073\/pnas.96.14.7992","article-title":"DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development","volume":"96","author":"Garc\u00eda-Domingo","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0070","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1172\/JCI24177","article-title":"Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms","volume":"115","author":"F\u00fctterer","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/cdd.2011.62","article-title":"Ablation of Dido3 compromises lineage commitment of stem cells in vitro and during early embryonic development","volume":"19","author":"F\u00fctterer","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0080","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1128\/MCB.23.9.3216-3225.2003","article-title":"Death inducer-obliterator 1 triggers apoptosis after nuclear translocation and caspase up-regulation","volume":"23","author":"Garc\u00eda-Domingo","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0085","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/onc.2012.115","article-title":"Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression","volume":"32","author":"Braig","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.celrep.2013.06.014","article-title":"Dido3 PHD modulates cell differentiation and division","volume":"4","author":"Gatchalian","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-5-2","article-title":"Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis","volume":"5","author":"Tognon","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0100","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1073\/pnas.0611132104","article-title":"Dido disruption leads to centrosome amplification and mitotic checkpoint defects compromising chromosome stability","volume":"104","author":"Trachana","year":"2007","journal-title":"PNAS"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/BJ20082131","article-title":"Sensitization of imatinib resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP","volume":"420","author":"Park","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0110","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1590\/1414-431X20143734","article-title":"A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia","volume":"47","author":"Xia","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0115","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0120","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0125","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders","volume":"108","author":"Bellanne\u00b4-Chantelot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0130","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1182\/blood-2005-12-4988","article-title":"Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders","volume":"107","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0135","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2016.03.008_bb0140","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0145","first-page":"184","article-title":"The JAK-STAT pathway and hematopoietic stem cells from the JAK2V617F perspective","volume":"1","author":"Staerk","year":"2012","journal-title":"JAKSTAT"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0150","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2016.03.008_bb0155","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.bcmd.2017.08.013","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000}}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T09:52:56Z","timestamp":1536832376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616300225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":31,"alternative-id":["S1079979616300225"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.03.008","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}